Does Rallies show 13F holders for LXRX?

Yes. Rallies tracks hedge fund and 13F ownership data for LXRX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is LXRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LXRX. It does not provide personalized investment advice.

LXRX (Lexicon Pharmaceuticals, Inc.) Stock Analysis - Hedge Fund Holdings

Lexicon Pharmaceuticals, Inc. (LXRX) is a publicly traded Healthcare sector company. As of May 21, 2026, LXRX trades at $2.23 with a market cap of $950.58M and a P/E ratio of -31.07. LXRX moved +4.23% today. Year to date, LXRX is +93.86%; over the trailing twelve months it is +287.72%. Its 52-week range spans $0.28 to $2.53. Analyst consensus is strong buy with an average price target of $4.03. Rallies surfaces LXRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns LXRX stock?

Hedge funds tracked by Rallies that own LXRX include Orbimed Advisors. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Lexicon Pharmaceuticals, Inc..

LXRX Key Metrics

Key financial metrics for LXRX
Metric	Value
Price	$2.23
Market Cap	$950.58M
P/E Ratio	-31.07
EPS	$-0.07
Dividend Yield	0.00%
52-Week High	$2.53
52-Week Low	$0.28
Volume	180
Avg Volume	0
Revenue (TTM)	$69.64M
Net Income	$-26.09M
Gross Margin	99.50%

Top Hedge Funds Holding LXRX

Orbimed Advisors holds 11.02M shares of LXRX, changed +88.57% as of Sep 30, 2024.

Latest LXRX News

Lexicon Pharmaceuticals Delivers $0.00 Q1 EPS, Beats $0.04 Loss Estimate — May 7, 2026
Lexicon’s PROGRESS Data Shows Pilavapadin 10 mg Reduces Pain at Week 8, Supports Phase 3 — Apr 17, 2026
Lexicon to Present SCORED Analysis with BMI-Independent Heart Failure, MACE Reductions and HFpEF Quality-of-Life Data — Mar 24, 2026
Lexicon Earns $10 Million Milestone as Novo Nordisk Launches LX9851 Phase 1 Trial — Mar 23, 2026
Lexicon Shows Sotagliflozin Cuts HbA1c, Weight and Hypoglycemia Events in CKD Subgroups — Mar 11, 2026

Recent LXRX Insider Trades

DEBBANE RAYMOND bought 2.00K (~$2.98K) on Feb 25, 2026.
DEBBANE RAYMOND bought 100.00K (~$147.00K) on Feb 23, 2026.
DEBBANE RAYMOND bought 100.00K (~$147.79K) on Feb 20, 2026.

LXRX Analyst Consensus

4 analysts cover LXRX: 0 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.03.

Common questions about LXRX

Who owns LXRX stock?: Hedge funds tracked by Rallies that own LXRX include Orbimed Advisors. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Lexicon Pharmaceuticals, Inc..
Does Rallies show 13F holders for LXRX?: Yes. Rallies tracks hedge fund and 13F ownership data for LXRX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is LXRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LXRX. It does not provide personalized investment advice.